 Patients will be stratified by PSA doubling time 3 months vs. 3-9 months and randomized in 1:1:1 fashion to one of three treatment arms: 1 Control arm consisting of degarelix monotherapy, 2 Experimental arm consisting of apalutamide in combination with degarelix, and 3 Experimental arm consisting of apalutamide, abiraterone acetate prednisone, and degarelix. Patients will be treated for a maximum duration of 52 weeks and then enter follow up phase until the time of PSA progression, development of metastasis, or patient withdrawal from study, whichever occurs first. Patients with PSA progression will be followed long term until the development of castration resistance, first metastasis, and death. 